PCR Reagents for Detection of (CAG) n Repeats in Huntington Disease
To the Editor: Recently Muglia et al. [1] reported in your journal a nonisotopic detection of (CAG) n repeats in the Huntington disease (HD) gene. We have read this article with great interest, as we use a similar method for the detection of the above [2, 3] .
There are many difficulties in the PCR conditions of examining CAG repeats in the HD gene and in the detection of PCR products on nondenaturating polyacrylamide gel by silver staining. As yet there is no standardized protocol for the detection of CAG repeats in the HD gene. Muglia et al. [1] reported factors that affect the utility of the PCR product from the HD region by using the known HD-1 and HD-3 primers [4] . They used a relatively high MgCl 2 concentration (2.0 mmol/L) without dimethyl sulfoxide in 35 cycles. When they applied Ͼ35 PCR cycles, they obtained high background of nonspecific bands. We do not see these bands in our method with the lowest possible MgCl 2 concentration (0.625 mmol/L), dimethyl sulfoxide (120 g/L) [3] instead of formamide, and 36 cycles. Figure 1 demonstrates four patients' results obtained by use of 8% nondenaturating polyacrylamide gel stained by the silver staining method [5] applied by Muglia et al.
We found that the amount of mispriming and other nonspecific products mainly depends on the origin of Taq polymerase and other conditions, such as the number of PCR cycles and the use of enhancer components. The latter were investigated by Muglia et al., but the origin of Taq polymerase was not indicated in the article. We found that Ampli-Taq (Perkin-Elmer, Norwalk, CT) and Taq polymerase from Promega (Madison, WI) gave sharper bands and less bacground than some others. 
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To the Editor:
Tó th et al. report a method of detection of (CAG) n repeats causing Huntington disease. They suggest some technical variations to our procedure. The major differences are the use of a lower MgCl 2 concentration (0.625 mmol/L) and the use of dimethyl sulfoxide (DMSO) (12%) instead of formamide. Before deciding to use formamide, we tried performing PCR with DMSO as reported in the published article. However, we achieved the optimum results by using formamide (35 mmol/L). This difference in results may be attributed to the fact that we did not attempt to decrease the MgCl 2 concentration while using DMSO. It is possible that the use of DMSO together with a lower concentration of MgCl 2 yields similar results to those obtained when using formamide and a MgCl 2 concentration of 2 mmol/L.
With respect to the Taq polymerase, we used Taq polymerase from Promega with the incubation buffer specified in our article. To the Editor:
Maria Mugulia Ofelia Leone
The deciding factor in whether to measure an analyte in the emergency out-of-hours period is whether the result will affect the immediate clinical management. Hemoglobin (Hb) A 1c is not included in the list of tests usually provided [1, 2] , but the unforeseen may occur. A transplant team was informed that kidneys and pancreas were available in another hospital from a 14-year-old girl who had suffered a cardiac arrest after a grand mal seizure. She had become hypernatremic and was infused with a 50 g/L dextrose solution. The surgeon was informed that the plasma glucose was 21 mmol/L and the question arose whether the hyperglycemia reflected undiagnosed diabetes mellitus. A Hb A 1c done on call immediately was 7.1%, indicating a very high probability that the patient had diabetes [3] . Normal oral glucose tolerance was found in only 4% of subjects with a Hb A 1c value of at least 7% in a metaanalysis study [4] . The pancreas was thus unsuitable, but the heart, liver, and kidneys were successfully transplanted. Decisions regarding the suitability of organs for transplantation must be made quickly. Hb A 1c was the appropriate choice in that context.
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Rapid, Highly Sensitive Immunoassay for Determination of Cardiac Troponin I in Patients with Myocardial Cell Damage
The aim of this study was to validate a new automated cardiac troponin I (cTnI) assay developed by Sanofi Diagnostic Pasteur (Marnes la Coquette, France) on the Access immunoassay system from the same manufacturer, and to evaluate its diagnostic sensitivity for early detection of myocardial damage. The assay is a two-site sandwich, immunochemiluminometric ELISA using two monoclonal antibodies that recognize different epitopes unique to the human cTnI isoform [1] . Pipetting, incubations, measurements, and data-reduction steps are performed on the Access analyzer, which produces the first test result in 20 min. The minimum detectable cTnI concentration, assessed by 10 replicate measurements in a single run of the zero calibrator serum supplied with the kit and defined as the cTnI value corresponding to the signal 3 SD greater than the mean found for this calibrator, was estimated as 0.01 g/L. The assay measured cTnI in serum and EDTA-anticoagulated plasma in the same way: Fresh specimens collected at the same time from subjects (n ϭ 24) with an increased concentration of cTnI gave similar results for serum and EDTAplasma (0.49 Ϯ 0.78 vs 0.46 Ϯ 0.74 g/L, respectively; P ϭ 0.48). Assay reproducibility was tested by assaying three control materials (from Sanofi) containing human cTnI at 0.28, 6.6, and 25.4 g/L plus two samples of pooled fresh serum (0.07 and 0.30 g/L, respectively). Withinrun CVs (n ϭ 30) were between 3.8% and 12.5%, and between-run CVs (n ϭ 10) ranged between 4.3% and 15.7%. Correlation studies were conducted with two alternative techniques for cTnI: Sanofi Diagnostics Pasteur ELISA manual assay and Opus immunometric assay (Behring Diagnostics, Westwood, MA), performed according to the manufacturers' current protocols [2, 3] . Linear regression equations were as follows: Access ϭ 1.43 Pasteur Ϫ 0.08 g/L (S y͉x ϭ 0.19, r ϭ 0.948, n ϭ 44), and Access ϭ 0.09 Opus ϩ 0.05 g/L (S y͉x ϭ 0.48, r ϭ 0.952, n ϭ 81). In particular, the Opus assay led to ϳ10-fold higher values than the two Sanofi assays.
We used the Access assay to measure concentrations of cTnI in sera from subjects in five groups: (a) 105 apparently healthy people, ages 22-84 years; (b) 44 patients with a typical history of myocardial infarction (MI) of Ͻ8 h duration; (c) 8 patients with severe muscular damage [total creatine kinase (CK) values 10 240 to 29 000 U/L] but no apparent cardiac injury; (d) 20 consecutive dialysis patients with no evidence of myocardial injury; and (e) 22 patients with unstable angina (diagnosis based on typical electrocardiogram changes during episodes of chest pain together with coronary arteriography, performed within 72 h of admission). Procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 1983.
We found that cTnI concentrations in 99% of the apparently healthy subjects were Յ0.03 g/L and in 88% were Յ0.01 g/L, the detection limit of the assay as defined above and determined with the zero calibrator. The highest value for cTnI in these samples was 0.063 g/L. To evaluate the diagnostic sensitivity of the Access cTnI in the early phase of MI, we analyzed a single peripheral venous blood sample obtained in our MI patients immediately after admission to the hospital before any revascularization treatment, e.g., thrombolysis (median time after the onset of chest pain, 210 min; range, 30 -450 min). For comparison, we also measured myoglobin and CK-MB mass. All three assays were performed on a single Access analyzer at the same time. The cutoff values were as follows: myoglobin, 60 g/L; CK-MB, 5.0 g/L; and cTnI, 0.03 g/L. In this population, the Access cTnI showed the same diagnostic sensitivity (29 positive of 44 MI patients, 66%) as myoglobin (28 of 44, 64%), the classical early cardiac marker, whereas the sensitivity of CK-MB mass deter-
